Big Pharma is gambling on specialized R&D. Will it pay off?

Large pharma companies are taking bigger swings on fewer targets, which can be a risky strategy.

By Kelly Bilodeau • May 20, 2026

Summer reads with unexpected lessons for biopharma leaders

From an inspiring rags-to-riches journey to a heroic rescue story at sea, here are a few books recommended by biopharma execs and what they can teach about leadership.

By Alexandra Pecci • May 19, 2026

Explore the Trendline➔

Tech for Clinical Trials

Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

By PharmaVoice staff

Regeneron immunotherapy combo comes up short in melanoma trial

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

By Ben Fidler • May 19, 2026

Race intensifies to lead next wave of obesity drugs as trial results loom

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

By Kelly Bilodeau • May 18, 2026

Sanofi’s vaccine bump; the new FDA commish

A look at how vaccine makers are scraping by, and at the incoming acting FDA head, Kyle Diamantas.

By PharmaVoice staff • May 15, 2026

Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech

The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.

By Meagan Parrish • May 15, 2026

FDA chief’s exit clouds already murky drug approvals

During Dr. Martin Makary’s tenure as commissioner, the FDA faced pushback over high-profile drug rejections for Replimune and UniQure.

By Kelly Bilodeau • May 14, 2026

India’s pharma industry is going global. But can it catch up to China?

A record  Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

By Kelly Bilodeau • May 13, 2026

Why the FDA’s push for real-time clinical trials could favor Big Pharma

The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.

By Alivia Kaylor • May 13, 2026

Cancer, immunology startups lead latest wave of stealth exits

A handful of recently debuted biotechs reveal where drug R&D is headed next.

By Alexandra Pecci • May 11, 2026

Protein degraders gain speed as Arvinas scores landmark approval

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

By Kelly Bilodeau • May 4, 2026

Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?

Results show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.

By Kelly Bilodeau • April 29, 2026

Obesity drugmakers chase weight loss. Biohaven is betting on muscles.

With many pharma companies focused on developing drugs that shed pounds, Biohaven is digging its heels into a clinical program based on an experimental myostatin inhibitor that builds muscle. 

By Alivia Kaylor • April 29, 2026

Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.

By Alexandra Pecci • April 28, 2026

Is pharma missing the boat on diagnostics?

Precision medicine is bringing pharma and diagnostics closer together, but there’s still a ways to go before the matchup is fully realized.

By Meagan Parrish • April 24, 2026

An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?

A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”

By Alexandra Pecci • April 22, 2026

Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. 

By Gwendolyn Wu • April 22, 2026

Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push

The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as the future of genetic medicines.

By Michael Gibney • April 21, 2026

Roche’s DAC investment; Big Pharma’s lavish CEO bumps

Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.

By PharmaVoice Staff • April 17, 2026

Can an LSD candidate do for anxiety what Spravato did for depression?

Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a potential approval.

By Meagan Parrish • April 17, 2026

Will cancer drugmakers ever conquer p53?

The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.

By Kelly Bilodeau • April 15, 2026

The era of Big Pharma’s one-size-fits-all pipeline is fading

Roche, AstraZeneca and Sanofi demonstrate how companies are following their own R&D paths.

By Kelly Bilodeau • April 13, 2026

Predictive analytics in pharma turns lab data into launch strategies

Explore how diagnostic insights become launch strategies with predictive analytics and real-world lab data.

April 13, 2026

Biotech’s IPO comeback; Trump’s tariff loophole for pharma

Biotech IPOs gain long-lost momentum, and pharma companies find a way around the White House’s harsh tariffs.

By PharmaVoice Staff • April 10, 2026

One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it.

Dr. Ebrahim Delpassand, founder and CEO of RadioMedix, played a pivotal role in advancing nuclear medicine as a new-generation cancer treatment, but his work is far from finished.

By Michael Gibney • April 9, 2026